Aktis Oncology, Inc.
Aktis Oncology is a biotechnology company developing targeted radiopharmaceutical medicines for the treatment of solid tumors. Its scientific approach investigates ways to deliver radioactive payloads to selected tumor tissues using targeting technologies, with the aim of improving precision in cancer treatment. Aktis conducts therapeutic research and clinical development, and its programs are investigational unless specifically supported by a regulatory approval. The company began public trading in 2026 and publishes issuer information through its investor relations website. Readers can use its official company and investor resources to examine the current clinical pipeline, securities filings and corporate announcements.
Company at a glance
Corporate information
- Company entity
- Aktis Oncology, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.aktisoncology.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Global Select Market: AKTS
targeted radiopharmaceuticals · alpha-emitting radioligands
solid tumors · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Aktis Oncology is a biotechnology company developing targeted radiopharmaceutical medicines for the treatment of solid tumors. Its scientific approach investigates ways to deliver radioactive payloads to selected tumor tissues using targeting technologies, with the aim of improving precision in cancer treatment. Aktis conducts therapeutic research and clinical development, and its programs are investigational unless specifically supported by a regulatory approval. The company began public trading in 2026 and publishes issuer information through its investor relations website. Readers can use its official company and investor resources to examine the current clinical pipeline, securities filings and corporate announcements.
Business, technology & evidence
- SecuritiesNasdaq Global Select Market: AKTS
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Aktis Oncology, Inc. ↗Aktis Oncology, Inc. ·
- Official issuer and R&D disclosure · Aktis Oncology, Inc. ↗Aktis Oncology, Inc. ·
- Official issuer and R&D disclosure · Aktis Oncology, Inc. ↗Aktis Oncology, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.